Advances in Small-Molecule Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advances in Small-Molecule Synthesis
Approaches in cyclization, palladium-catalyzed cross couplings, fluorination, and natural product synthesis help to optimize routes for select drugs.


Pharmaceutical Technology
Volume 34, Issue 12, pp. 40-42

References

1. G. Rassias et al., Org. Proc. Res. Dev. 14 (1), 92–98 (2010).

2. B. Halford, Chem. Eng. News 88 (41), 7 (2010).

3. M. Jacoby, Chem. Eng. News 88 (7), 60 (2010).

4. N.T.S. Phan, M. Van Der Sluys, and C.W. Jones, Adv. Synth. Catal. 348 (6), 609–679 (2006).

5. C.W. Jones et al., Organometallics 24 (18), 4351–4361 (2005).

6. C.W. Jones et al., Adv. Synth. Catal 347 (1), 161–171 (2005).

7. M. Beller et al., Angew. Chem. Int. Ed. 49 (47), 8988–8992 (2010).

8. K. Stradiotto et al., Angew. Chem. Int. Ed., 49 (24) 4071–4074 (2010).

9. M. Stradiotto et al., Angew. Chem. Int. Ed. 49 (46) 8686–8690 (2010).

10. D. Fischer and R. Sarpong, J. Amer. Chem. Soc. 132 (17), 5926–5927 (2010).

11. C. Drahl, Chem. Eng. News 88 (17), 11 (2010).

12. T. Pingping, T Furuya, and T. Ritter J. Am. Chem. Soc. 132 (34), 12150–12154 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here